DCPH - Deciphera Pharma announces public offering of $125M shares

• Deciphera Pharma ( NASDAQ: DCPH ) said it it expects to offer and sell $125M shares of its common stock in an underwritten public offering.
• Deciphera would grant the underwriters a 30-day option to purchase up to an additional $18.75M of shares of common stock offered in the public offering.
• Deciphera would use the net proceeds from the offering to fund its planned Phase 3 INSIGHT study of QINLOCK versus sunitinib in second-line GIST patients with mutations in KIT exon 11 and 17/18 only; to fund the development of its pipeline.

For further details see: